Preclinical neuroscience

Target the repair pathway. Not the trip.

Xycota is developing a low-dose psilocybin capsule designed to be taken at home. Our first clinical question is whether it could help people with mild PTSD.

XYCO-02 · Canadian clinical trial application in preparation · Preclinical

Illustration. Not experimental data.

Published Preclinical Foundation & Proposed Human Trial

From a rat study to a planned PTSD study

In a 2026 study in a Fragile X rat model, repeated low doses of psilocybin improved object-recognition memory. The improvement remained when researchers blocked the receptor tied to the psychedelic trip (5-HT2A) and disappeared when they blocked a brain-signaling receptor called TrkB.

That result was observed in rats, not people. Xycota’s planned clinical study will test whether a low-dose capsule can improve PTSD symptoms and whether related changes can be measured in blood.

Observed preclinical result Ascone et al., 2026 (Fmr1-Δexon 8 rats)

Memory rescue depended on TrkB, not 5-HT2A

Repeated low-dose oral psilocybin (0.1 mg/kg every other day) rescued object-recognition memory and normalized prefrontal mBDNF/TrkB/AKT signaling:

1. Psychedelic Receptor Blocked (5-HT2A)

Psilocybin + M100907 (5-HT2A antagonist)

Memory rescue remained

2. Neurotrophic Receptor Blocked (TrkB)

Psilocybin + ANA-12 (1.0 mg/kg TrkB blocker)

Memory rescue disappeared

Peer-reviewed in Neuropsychopharmacology (July 2026) · DOI: 10.1038/s41386-026-02361-x

Planned in people XYCO-02 · Mild PTSD

Proposed 28-day at-home clinical study

Double-blind, placebo-controlled study of a standardized, sub-perceptual oral psilocybin capsule in adults with mild PTSD, evaluating two readouts:

Clinical Symptom Score

CAPS-5 PTSD Scale

Assesses whether PTSD symptoms improve compared with matched placebo.

Supporting Blood Readout

Serum BDNF in Blood

Measured alongside CAPS-5. A blood change alone does not prove brain repair.

Status: Preclinical · Health Canada CTA in preparation with CRO partner KGK Science

Figure 1 · Preclinical rat finding and planned human mild-PTSD study architecture Source: Ascone F, Buzzelli V, Mottarlini F, et al., Neuropsychopharmacology 2026; 51(8):1454-1463 (left panel) · Proposed XYCO-02 protocol in preparation with KGK Science (right panel).
A man sitting on a porch step at sunrise holding a mug.

WHY AT HOME

A different setting for treatment

Supervised psychedelic sessions can run six to eight hours in a clinic. XYCO-02 is designed for a different setting: a capsule taken at home, at a dose intended to produce no noticeable psychedelic effects. Whether that works is what the planned study will test.

See the planned study →

Preclinical CNS Pipeline

Two programs at a glance

Full pipeline and regulatory details →
Program Approach Indication Stage Next step
XYCO-02
Lead candidate
Sub-perceptual oral psilocybin capsule Mild PTSD Preclinical Complete Canadian Clinical Trial Application and submit with KGK Science
XYCO-01
Follow-on candidate
Exosome-encapsulated psilocin Frontotemporal dementia Preclinical FDA Orphan Drug Designation application filed; preclinical FTD animal study planned after XYCO-02 advances
What “sub-perceptual” means

Sub-perceptual describes the design goal for XYCO-02. The low-dose oral regimen is formulated to stay below the threshold of noticeable psychedelic effects. Whether participants with mild PTSD can distinguish XYCO-02 from placebo during repeated dosing remains an open question.

The people behind the science

Full biographies and credentials →
Dr. Marvin S. Hausman, MD, Chief Scientific Officer & Co-Founder of Xycota Biosciences

Chief Scientific Officer & Co-Founder

Dr. Marvin S. Hausman, MD

Co-authored the 2026 Fragile X rat study in Neuropsychopharmacology. Immunologist, board-certified urological surgeon, former U.S. Public Health Service Surgeon at the NIH, and pharmaceutical developer with over 35 years in CNS and clinical drug development.

Brad Listermann, Co-Founder & CEO of Xycota Biosciences

Co-Founder & CEO

Brad Listermann

Leads Xycota’s corporate strategy, intellectual property, capital formation, and technology infrastructure. Technology entrepreneur and inventor with filed patent applications spanning AI, cybersecurity, and cryptographic verification, paired with over two decades of capital-markets leadership.

Dr. Anthony Smith, PhD, Senior Lab Operations Manager at Xycota Biosciences

Senior Lab Operations Manager

Dr. Anthony Smith, PhD

Directs Xycota’s laboratory operations and the Colorado exosome and liposome formulation programs. Holds a PhD in Molecular and Cellular Biology from Oregon State University and previously served as President and Chief Science Officer of EVIO Labs and Laboratory Director at Kaycha Labs.

External academic and CRO collaborators (not Xycota employees)

Associate Professor Viviana Trezza, PhD

Roma Tre University

Associate Professor Viviana Trezza, PhD

Associate Professor of Pharmacology and senior author of the 2026 Fragile X rat study.

Dr. Louise Hecker, PhD

Baylor College of Medicine

Dr. Louise Hecker, PhD

Senior author of the 2025 npj Aging study on psilocin and cellular survival in aged mice.

Andrew Charrette, MSc

KGK Science (CRO Partner)

Andrew Charrette, MSc

Director of Regulatory Affairs advising on Xycota’s Health Canada CTA preparation for XYCO-02.